Cannabinoid oral spray - Aphria/Medlab

Drug Profile

Cannabinoid oral spray - Aphria/Medlab

Alternative Names: NanaBidial; NanaBis; Nanocelle™ CBD

Latest Information Update: 25 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aphria; Medlab
  • Developer Medlab
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Cyclohexenes; Muscle relaxants; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Pain

Most Recent Events

  • 27 Oct 2017 Medlab plans a pilot pharmacokinetics, safety and tolerability trial of NanaBidial in healthy volunteers in Australia (Buccal) in February 2018 (ACTRN12617001491358)
  • 22 Aug 2016 Early research in Pain in Australia (PO)
  • 22 Aug 2016 Medlab plans a phase I/II study in Pain in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top